Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report.

Lo SC Sr, Yeh HJ Sr

Cureus20 Jan 2026

PMID41728571 (opens in a new tab)PMCIDPMC12919507 (opens in a new tab)DOI10.7759/cureus.101908 (opens in a new tab)PepBankPUB-41728571
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown robust efficacy in glycemic control, weight reduction, and cardiovascular protection, but concerns remain regarding rare adverse events such as acute pancreatitis. We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and dyslipidemia who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy. He presented with epigastric pain and elevated lipase, while abdominal ultrasound revealed only mild pancreatic parenchymal heterogeneity without peripancreatic fluid collection. The patient improved with conservative management, and semaglutide was discontinued in favor of linagliptin, with no recurrence of symptoms during three months of follow-up. This case highlights the potential risk of pancreatitis in patients with multimorbidity, a population frequently excluded from randomized controlled trials and underrepresented in real-world prescribing due to socioeconomic barriers. Clinicians should remain vigilant when prescribing semaglutide to patients with multiple underlying chronic conditions, and further studies focusing on multimorbid populations are warranted to clarify its safety profile.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A 59-year-old man with type 2 diabetes developed acute pancreatitis after 2.5 years of weekly semaglutide therapy.

    In plain wordsOne man with type 2 diabetes developed inflammation of the pancreas after 2.5 years of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableAcute pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 2.5 yearsAs given in this study (human).

    Source sentences

    Summary
    We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and dyslipidemia who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy.
  2. 02HumanCase report or seriesSafety outcome

    A man who developed acute pancreatitis on semaglutide presented with epigastric pain and elevated lipase.

    In plain wordsOne man with pancreas inflammation on semaglutide had upper belly pain and a raised pancreas enzyme level.

    Peptide
    Semaglutide
    Outcome
    IncreaseElevated lipase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 2.5 yearsAs given in this study (human).

    Source sentences

    Summary
    He presented with epigastric pain and elevated lipase
    1 context sentence
    Summary · context
    We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and dyslipidemia who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy.
  3. 03HumanCase report or seriesSafety outcome

    In a man with acute pancreatitis on semaglutide, abdominal ultrasound revealed only mild pancreatic parenchymal heterogeneity without peripancreatic fluid collection.

    In plain wordsIn one man with pancreas inflammation on semaglutide, an ultrasound showed only mild changes in the pancreas and no fluid around it.

    Peptide
    Semaglutide
    Outcome
    Not applicableAbdominal ultrasound findings
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 2.5 yearsAs given in this study (human).

    Source sentences

    Summary
    abdominal ultrasound revealed only mild pancreatic parenchymal heterogeneity without peripancreatic fluid collection.
    1 context sentence
    Summary · context
    We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and dyslipidemia who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy.
  4. 04HumanCase report or seriesSafety outcome

    After semaglutide was stopped and replaced with linagliptin, the patient improved with conservative management and had no recurrence of symptoms in three months.

    In plain wordsAfter semaglutide was stopped, one man improved and had no return of symptoms during three months of follow-up.

    Peptide
    Semaglutide
    Outcome
    No significant changeRecurrence of symptoms after semaglutide discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 2.5 yearsAs given in this study (human).

    Source sentences

    Summary
    The patient improved with conservative management, and semaglutide was discontinued in favor of linagliptin, with no recurrence of symptoms during three months of follow-up.
    1 context sentence
    Summary · context
    We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and dyslipidemia who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.